Related Articles
Revolutionizing Cancer Care With Genomic Testing
In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a…
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with…
Treatment Considerations for Fit Elderly BPDCN Patients
Dr. Schiller will discuss how their treatment approach would differ for a 74-year-old BPDCN patient with only well-controlled type 2 diabetes as a comorbidity and…
Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS
Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic…
April Roundtable Roundup: B-cell Lymphoma
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse…
FDA Grants Accelerated Approval to Tovorafenib in Pediatric Low-Grade Glioma
The FDA has approved the new drug application of tovorafenib for the treatment of pediatric low-grade glioma.
Patient Case: Pathology of Graft Versus Host Disease
Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty…
Combating Resistance Mechanisms to Treatment in Thyroid Cancer
Lova Sun, MD, MSCE, discusses resistance mechanisms against targeted agents for the treatment of thyroid cancer.
FDA Grants Accelerated Approval to Tovorafenib in Pediatric Low-Grade Glioma
The FDA has approved the new drug application of tovorafenib for the treatment of pediatric low-grade glioma.